4-amino-2-((4-((E)-2-(3,5-dimethoxystyryl))phenylamino)methyl)phenol | 1446410-66-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-amino-2-((4-((E)-2-(3,5-dimethoxystyryl))phenylamino)methyl)phenol
• 英文别名: 4-amino-2-[[4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]anilino]methyl]phenol
• CAS: 1446410-66-7
• 化学式: C₂₃H₂₄N₂O₃
• 分子量: 376.455
• InChiKey: JTYDXZIYYOSLSG-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  76.7
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-amino-2-((4-((E)-2-(3,5-dimethoxystyryl))phenylamino)methyl)phenol 、 丙酮 在 sodium cyanoborohydride 作用下， 以 乙腈 为溶剂， 以21%的产率得到2-((4-((E)-2-(3,5-dimethoxystyryl))phenylamino)methyl)-4-(isopropylamino)phenol
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer’s Disease

  摘要：

  A series of multitarget-directed resveratrol derivatives was designed and synthesized for the treatment of Alzheimer's disease (AD). In vitro studies indicated that most of the target compounds exhibit significant inhibition of self-induced beta-amyloid (A beta) aggregation and Cu(II)-induced A beta(1-42) aggregation and acted as potential antioxidants and biometal chelators. In particular, compounds 5d and 10d are potential lead compounds for AD therapy (5d, IC50 = 7.56 mu M and 10d, IC50 = 6.51 mu M for self-induced A beta aggregation; the oxygen radical absorbance capacity assay using fluorescein (ORAC-FL) values are 4.72 and 4.70, respectively). Moreover, these compounds are capable of disassembling the highly structured A beta fibrils generated by self- and Cu(II)-induced A beta aggregation. Furthermore, 5d crossed the blood-brain barrier (BBB) in vitro and did not exhibit any acute toxicity in mice at doses of up to 2000 mg/kg. Taken together, the data indicate that 5d is a very promising lead compound for AD.

  DOI：

  10.1021/jm400567s
• 作为产物：
  描述：

  对硝基苯甲醛 在 吡啶 、 sodium tetrahydroborate 、 乙醇 、 sodium methylate 、 三溴化磷 、 对甲苯磺酸 、 tin(ll) chloride 作用下， 以 甲醇 、 乙醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 4-amino-2-((4-((E)-2-(3,5-dimethoxystyryl))phenylamino)methyl)phenol
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer’s Disease

  摘要：

  A series of multitarget-directed resveratrol derivatives was designed and synthesized for the treatment of Alzheimer's disease (AD). In vitro studies indicated that most of the target compounds exhibit significant inhibition of self-induced beta-amyloid (A beta) aggregation and Cu(II)-induced A beta(1-42) aggregation and acted as potential antioxidants and biometal chelators. In particular, compounds 5d and 10d are potential lead compounds for AD therapy (5d, IC50 = 7.56 mu M and 10d, IC50 = 6.51 mu M for self-induced A beta aggregation; the oxygen radical absorbance capacity assay using fluorescein (ORAC-FL) values are 4.72 and 4.70, respectively). Moreover, these compounds are capable of disassembling the highly structured A beta fibrils generated by self- and Cu(II)-induced A beta aggregation. Furthermore, 5d crossed the blood-brain barrier (BBB) in vitro and did not exhibit any acute toxicity in mice at doses of up to 2000 mg/kg. Taken together, the data indicate that 5d is a very promising lead compound for AD.

  DOI：

  10.1021/jm400567s

文献信息

• Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer’s Disease
  作者：Chuanjun Lu、Yueyan Guo、Jun Yan、Zonghua Luo、Hai-Bin Luo、Ming Yan、Ling Huang、Xingshu Li

  DOI：10.1021/jm400567s

  日期：2013.7.25

  A series of multitarget-directed resveratrol derivatives was designed and synthesized for the treatment of Alzheimer's disease (AD). In vitro studies indicated that most of the target compounds exhibit significant inhibition of self-induced beta-amyloid (A beta) aggregation and Cu(II)-induced A beta(1-42) aggregation and acted as potential antioxidants and biometal chelators. In particular, compounds 5d and 10d are potential lead compounds for AD therapy (5d, IC50 = 7.56 mu M and 10d, IC50 = 6.51 mu M for self-induced A beta aggregation; the oxygen radical absorbance capacity assay using fluorescein (ORAC-FL) values are 4.72 and 4.70, respectively). Moreover, these compounds are capable of disassembling the highly structured A beta fibrils generated by self- and Cu(II)-induced A beta aggregation. Furthermore, 5d crossed the blood-brain barrier (BBB) in vitro and did not exhibit any acute toxicity in mice at doses of up to 2000 mg/kg. Taken together, the data indicate that 5d is a very promising lead compound for AD.